You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 153 No. 13, 12 JULY 1993 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Review Article
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Low Levels of High-Density Lipoprotein Cholesterol (Hypoalphalipoproteinemia)

An Approach to Management

Robert S. Rosenson, MD

Arch Intern Med. 1993;153(13):1528-1538.


Abstract



Clinical management of dyslipidemias has focused primarily on the low-density lipoprotein cholesterol (LDL-C) fraction; however, lipid disorders accompanied by low levels of high-density lipoprotein cholesterol (HDL-C) (hypoalphalipoproteinemia) are common, particularly among subjects with the diagnosis of coronary artery disease prior to age 55 years. The therapeutic objectives for high-risk subjects with dyslipidemias is directed initially toward reduction of the LDL-C fraction; thereafter, aggressive efforts aimed at raising the HDL-C fraction may be warranted. Strategies for raising the HDL-C fraction start with hygienic measures that include aerobic exercise, weight loss, smoking cessation, withdrawal of agents secondarily lowering HDL-C, and estrogen replacement. Pharmacotherapy selected according to the dyslipidemia that accompanies the HDL-C disorder is indicated for subjects who manifest premature coronary artery disease or who have a familial history of coronary artery disease and hypoalphalipoproteinemia.

(Arch Intern Med. 1993;153:1528-1538)



Author Affiliations



From the Preventive Cardiology Center, Section of Cardiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease : A Working Group Report
Gotto
Circulation 2001;103:2213-2218.
FULL TEXT  

Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study
Zema
J Am Coll Cardiol 2000;35:640-646.
ABSTRACT | FULL TEXT  

New Perspectives on the Management of Low Levels of High-Density Lipoprotein Cholesterol
Harper and Jacobson
Arch Intern Med 1999;159:1049-1057.
ABSTRACT | FULL TEXT  

Beyond Low-Density Lipoprotein Cholesterol: A Perspective on Low High-Density Lipoprotein Disorders and Lp(a) Lipoprotein Excess
Rosenson
Arch Intern Med 1996;156:1278-1284.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.